Digital Microfluidic Nucleic Acid Testing Patents: Leaders & Trends 2026
- 31.7% concentration. The top 5 ranked assignees hold 191 of 603 records in scope — a genuinely concentrated field, not a fragmented one.
- Filing has cooled from its 2017 peak. 64 records published that year against 5 so far in 2026, with the 2021→2024 span down 33% (36 to 24) — though 2025-26 figures are still filling in under publication lag.
- Lab apparatus dominates the claim map. B01L appears on 63.8% of the 603 records, more than double the next largest class, G01N at 39.0%.
Filing growth compares 2021 (36 records) with 2024 (24) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 603 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This dataset tracks 603 patent families published between 2015 and mid-2026 that combine digital microfluidic actuation — electrowetting, droplet transport, droplet-based reagent handling — with the specific reliability problems that show up when you try to run nucleic acid testing on a chip: droplet transport reliability, biofouling, thermal cycling control, reagent storage stability and multiplexed assay design. It is a narrower cut than digital microfluidics broadly; the search string requires both the actuation mechanism and at least one of these named failure modes or design constraints in the claims or description.
The scope spans lab-on-chip hardware (B01L), analytical instrumentation (G01N), and the enzymatic/DNA measurement methods (C12Q) that ride on top of the actuation layer, which is why a single record often carries claims across several IPC classes at once.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 603 records: how filing volume has moved year over year, and which technical subclasses carry the claims.
A 2017 peak followed by a multi-year pullback
Filings peaked at 64 in 2017. The 2021-to-2024 window, the most recent span not distorted by publication lag, shows a 33% decline (36 down to 24). Treat 2025 and 2026 numbers as incomplete rather than as evidence of a further drop — publication typically lags filing by around 18 months.
Lab apparatus claims dominate, DNA methods are a minority layer
B01L (lab apparatus) touches 63.8% of the 603 records and G01N (material analysis) 39.0%, meaning most of the claim activity sits in the hardware and instrumentation layer rather than in the biochemistry itself. C12Q (enzyme/DNA measurement methods) sits at 13.8%, and C12N (microorganisms/genetic engineering) at just 5.6% — the assay-method layer is comparatively lightly claimed relative to the actuation hardware around it.
Shares are the percentage of the 603 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Digital Microfluidic Nucleic Acid Testing with Eureka
This page is one run against one query. Ask Eureka your own question about digital microfluidic nucleic acid testing and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited prior art in this space
US7816121B2 — Droplet actuation system and method
A droplet actuation system including a substrate with electrodes for conducting droplet operations, temperature control means for heating and/or cooling a region of the device so a droplet can be transported to a heating zone, and a means for effecting a magnetic field near one or more electrodes sufficient to immobilize magnetically responsive beads in a droplet during operations, all under a processor controlling the electrodes and temperature control.Filed by Advanced Liquid Logic, published 2010-10-19. Combines electrode-driven droplet transport, on-chip thermal control and magnetic bead immobilization in a single claimed system.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20030012483A1 | Microfluidic control for waveguide optical switches, variable attenuators, and other optical devices | 303 |
| 2 | WO2011002957A2 | Droplet actuator devices and methods | 275 |
| 3 | US20110048951A1 | Digital microfluidics based apparatus for heat-exchanging chemical processes | 222 |
| 4 | US7815871B2 | Droplet microactuator system | 210 |
| 5 | US7816121B2 | Droplet actuation system and method | 185 |
| 6 | US7763471B2 | Method of electrowetting droplet operations for protein crystallization | 169 |
| 7 | WO2016161400A1 | Devices and methods for sample analysis | 149 |
| 8 | US20130288254A1 | Droplet Actuator and Droplet-Based Techniques | 147 |
| 9 | US20120132528A1 | Methods of Dispensing and Withdrawing Liquid in an Electrowetting Device | 122 |
| 10 | US20160129437A1 | Instrument and cartridge for performing assays in a closed sample preparation and reaction system employing e… | 110 |
Citation counts favour older filings simply because they have had longer to accumulate citations inside this corpus — read them as a signal of influence on the field, not as a ranking of current relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers say about the field
Three figures worth sitting with before deciding where to file or who to watch.
A short list of firms controls a third of the field
The top 5 ranked assignees combine for 191 of 603 records (31.7%), and the top 10 combine for 306 (50.7%) — more than half the entire dataset. That is a concentrated field: a new entrant is not filing into open ground but into a claim map already shaped by a handful of players.
Activity has pulled back from its 2017 high
Filings peaked in 2017 at 64 and the last complete three-year window shows a 33% decline. That is a real cooling signal, not a data artefact — though the 2025-26 counts are too fresh to read given typical 18-month publication lag.
Hardware claims outnumber assay-method claims nearly 5 to 1
B01L (lab apparatus) appears on 385 of 603 records versus 83 for C12Q (enzyme/DNA measuring methods). Most of the documented invention activity is in the actuation and device layer, not in the nucleic-acid assay chemistry running on top of it.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to digital microfluidic nucleic acid testing, with the prior art for and against each one.
Who is filing, and where the gate sits
The leader holds 48 records; by fifth place that has fallen to 26, and by tenth place to 21 — a steep drop-off followed by a long tail of the remaining ranked assignees, each holding only a handful of families.
One firm sits well clear of the rest
The leading assignee's 48 records is nearly double the fifth-placed firm's 26, signalling a company that has built a defensive thicket around its core droplet-actuation hardware rather than one still exploring the space.
A tight cluster just behind the leader
From fifth to tenth place the record counts sit close together (26 down to 21), suggesting a competitive second tier rather than a single clear runner-up — worth watching for consolidation or licensing activity.
Co-filing is rare and concentrated
Only 10 co-assignee pairs appear in the dataset, and the strongest of them links a diagnostics firm with a droplet-actuation specialist. Co-filing here reads as targeted technology-licensing partnerships rather than a broad collaborative norm.
| Assignee | Recent year | YoY |
|---|---|---|
| Miroculus Inc | 0 | — |
| GenMark Diagnostics Inc | 0 | — |
| Abbott Laboratories | 0 | — |
| Advanced Liquid Logic Inc | 0 | — |
| Nicoya Lifesciences Inc | 0 | — |
| Lightcast Discovery Ltd | 0 | — |
| Illumina Inc | 0 | — |
| SeeReal Technologies SA | 0 | — |
Where to take this analysis
The dataset points to a concentrated hardware layer and a thinner assay-method layer. Two directions follow from that.
Map the leader's claim boundaries precisely
With one assignee holding 48 records and a tight second tier close behind, understanding exactly where the leader's droplet-actuation claims start and stop is the first step before committing engineering resource to that layer.
Explore claim scope in EurekaTest the under-claimed branches
Biofouling-resistant coatings and reagent storage stability sit behind the core actuation claims in filing density. A first claim drafted around one of these narrower failure modes may face materially less prior art.
Run a white space search in EurekaCommon questions on this landscape
The ranked assignee list is led by a single firm holding 48 of the 603 records in scope, well ahead of the fifth-placed firm at 26. The top 5 assignees combined hold 191 records — 31.7% of the entire dataset — and the top 10 combined hold 306, or 50.7%. That means over half of all documented activity in this space traces back to just ten organisations, so a freedom-to-operate review should start with that group rather than trying to survey the full 100-company ranking.
Filing peaked in 2017 at 64 records and has trended down since; the most recent complete three-year window, 2021 to 2024, shows a 33% decline from 36 to 24 filings. That is a real pullback, not noise. However, 2025 and 2026 figures in this dataset are still incomplete because publication typically lags actual filing by about 18 months, so it would be a mistake to read the very newest years as continuing that decline — they simply have not finished filling in yet.
Lab apparatus and device claims (IPC class B01L) appear on 63.8% of the 603 records in scope, making it by far the largest technical category, ahead of material analysis and testing (G01N) at 39.0%. Enzyme and DNA measurement methods (C12Q) sit at just 13.8%, and genetic engineering methods (C12N) at 5.6%. In practical terms, most of the patented invention work is happening in the microfluidic hardware and instrumentation layer, not in the underlying nucleic-acid assay chemistry.
Relative to the dense claim coverage on core droplet actuation and lab apparatus, narrower failure-mode areas such as biofouling-resistant electrode coatings, closed-loop droplet transport error correction, long-term on-chip reagent storage stability and multiplexed thermal zoning show thinner filing density in this dataset. These are still real engineering problems named directly in the search scope, which suggests they have not yet accumulated the same defensive thicket as the core actuation hardware. A first claim drafted narrowly around one of these mechanisms is likelier to clear prior art than one aimed at general droplet transport.
US7816121B2, assigned to Advanced Liquid Logic and published in 2010, claims a droplet actuation system combining electrode-driven droplet transport, on-chip temperature control for heating or cooling a droplet, and a magnetic field mechanism to immobilize magnetically responsive beads during droplet operations, all under a single controlling processor. It is one of the most-cited records in this landscape at 210 citations, reflecting how foundational its combination of transport, thermal control and bead handling has been to later filings. Anyone designing a droplet-based thermal cycling or bead-based extraction workflow should review its claim boundaries closely before finalizing an architecture.
Research Digital Microfluidic Nucleic Acid Testing in depth with Eureka
Go past this page: query the whole digital microfluidic nucleic acid testing corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.